YKL-40 and risk of incident cancer in early type 2 diabetes: a Danish cohort study
YKL-40 was associated with the risks of liver and bladder cancers, clearly outperforming CRP for these cancers. This suggests distinct prognostic roles for YKL-40 and CRP, and highlights YKL-40 as a promising biomarker for liver cancer.
Authors
- Kurt Højlund (ORCID: https://orcid.org/0000-0002-0891-4224)
- Alisa D. Kjærgaard (ORCID: https://orcid.org/0000-0003-3899-1324)
- Verena Hirschberg (ORCID: https://orcid.org/0000-0002-3600-1430)
- Reimar W. Thomsen (ORCID: https://orcid.org/0000-0001-9135-3474)
- Michael Hecht Olsen (ORCID: https://orcid.org/0000-0003-2230-5780)
- Niels Jessen (ORCID: https://orcid.org/0000-0001-5613-7274)
- Peter Vestergaard (ORCID: https://orcid.org/0000-0002-9046-2967)
- Allan Vaag (ORCID: https://orcid.org/0000-0002-3690-2191)
- Torben Hansen (ORCID: https://orcid.org/0000-0001-8748-3831)
Institutions
- University of Copenhagen (DK)
- Steno Diabetes Centers (DK)
- Aarhus University (DK)
- Aalborg University Hospital (DK)
- Novo Nordisk Foundation (DK)
- Odense University Hospital (DK)
- Aarhus University Hospital (DK)
- Copenhagen University Hospital (DK)
- Skåne University Hospital (SE)
- Holbæk Sygehus (DK)
Publication Details
- Journal
- British Journal of Cancer
- Published
- 2025-04-05
- DOI
- https://doi.org/10.1038/s41416-025-02996-5
- Primary Topic
- Studies on Chitinases and Chitosanases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Aarhus Universitet
- Aarhus Universitetshospital
- Novo Nordisk
- Sundhedsstyrelsen
- Novo Nordisk Fonden
- Diabetesforeningen